Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc.

ELDNNYSE / NASDAQHealthcareSmall cap

$1.78-$0.12 (-6.3%)

Last close · Data as of Nov 20, 2026

Market cap
$277.9M
P/E
-6.1x
EV / EBITDA
-3.1x
Revenue
$0.00
ROCE
-55.3%

+28.1% over the last year

Eledon Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-21.1%
3M
-49.4%
6M
-53.6%
1Y
+28.1%
5Y
-66.5%

52-week range

Day change -$0.12 (-6.3%) from $1.90 to $1.78 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ELDN, bought on each weekday since 2021.

News & filings

What Eledon Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 45.6 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 7.40 times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).

Read moreShow less

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Sector
Healthcare
Shares outstanding
75.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$277.9M
P/E
-6.1x
P/B
3.4x
EV / EBITDA
-3.1x
52-week high
$4.21
52-week low
$1.39

Profitability

ROE
-56.3%
ROCE
-55.3%
ROIC
-111.6%
ROA
-27.0%

Growth

Revenue
$0.00
Net profit growth, 1Y
26.1%
Free cash flow
-$62.3M

Solvency

Current ratio
7.40
Debt / Equity
0.01
Debt / Assets
0.00
CFO / Net profit
1.37
Cash / Market cap
8.2%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Eledon Pharmaceuticals, Inc. revenue and net profit by fiscal year
Eledon Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$88.0M
FY2023$0.00-$116.5M
FY2024$0.00-$36.2M
FY2025$0.00-$45.6M

Cash flows

FY2025: -$62.3M from operations, -$62.3M free after investment (dashed).

Eledon Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Eledon Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$28.4M-$28.4M
FY2023-$39.5M-$39.5M
FY2024-$47.3M-$47.3M
FY2025-$62.3M-$62.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$82.9M
Net profit
-$45.6M
Cash from operations
-$62.3M
Free cash flow
-$62.3M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$82.9M-$45.6M-$62.3M-56.3%—+26.1%

Monthly returns

Month-by-month returns of ELDN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$169.0M
Liabilities$87.9M
Equity$81.1M
Paid-in capital$482.2M
Retained earnings-$401.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ELDN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

Not shown (no positive earnings and no EV / Sales): Eledon Pharmaceuticals, Inc., Anavex Life Sciences Corp.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Eledon Pharmaceuticals, Inc.ELDNthis company$277.9M-6.1x3.4x-56.3%-3.1x
Alpha Teknova, Inc.TKNO$291.1M-16.9x4.2x-25.1%-30.9x
OraSure Technologies, Inc.OSUR$287.1M-4.2x0.8x-20.2%-1.7x
Niagen Bioscience, Inc.NAGE$278.8M16.0x3.6x22.7%13.8x
Quantum-Si incorporatedQSI$278.7M-2.8x1.3x-46.0%-2.8x
Entrada Therapeutics, Inc.TRDA$271.7M-1.9x0.9x-47.0%-1.5x
Anavex Life Sciences Corp.AVXL$261.3M-5.6x2.8x-48.9%—
Akebia Therapeutics, Inc.AKBA$260.3M-48.7x8.0x-16.4%5.9x
Fate Therapeutics, Inc.FATE$257.6M-1.9x1.2x-65.8%-2.1x
Peer median—-3.5x2.0x-35.6%-1.7x

Year-to-date ROI

ELDN since 1 January, against earlier years.

Historical volatility

ELDN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$83.3M
Research and developmentResearch And Development$66.3M
Total expensesTotal Expenses$83.3M
Pretax incomePretax Income-$45.6M

Learn while you research

Academy chapters picked for Eledon Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →